ShangPharma opens pilot plant in Shanghai
For pharma development and cGMP manufacturing
The new multi-purpose pharmaceutical development and cGMP manufacturing facility will allow ShangPharma to support its clients Phase II and Phase III trials, expanding its service offering to include process and formulation r&d, analytical method development and validation, and cGMP manufacturing of intermediates and APIs.
Previously the CRO/CMO provided clients with materials for early discovery and GLP toxicology testing and Phase I clinical trials.
ShangPharma said it might further expand its manufacturing facilities if there is demand for commercial manufacturing of FDA- or EMEA-approved drugs.
The Fengxian facility will operate as a wholly owned subsidiary of the company under the name China Gateway Pharmaceutical Development Co. It includes a pilot plant that supports six separate bays with reactor capacities ranging from 200 to 3,000 litres and other speciality bays with reactor capacities ranging from 50 to 2000 litres for high temperature, cryogenics, highly toxic and pressurised reactions, including hydrogenation.
The company said there are also two cleanroom suites rated at Class 100,000 for isolation, 10 kilo-lab suites for bothnon-cGMP and cGMP manufacturing, as well as a large r&d laboratory for analytical, formulation and process development activities.
In addition, there are separate buildings for utilities, materials management, warehouse storage and waste water treatment with room for further expansion to support commercial manufacturing activities.
Testing of raw materials, intermediates and final products will be carried out at the site. An independent quality assurance department will ensure that materials are manufactured in accordance with cGMP requirements and that established standard operating procedures are followed, the firm said.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Guardtech open partnership with Dry Air to offer game-changing dry room facility installations for Battery industry and beyond
Suffolk-based cleanroom construction specialists the Guardtech Group are set to combine their envelope knowhow with Dry Air’s groundbreaking sealing techniques and HVAC expertise
Manufacturing
AstraZeneca to expand Virginia manufacturing facility with $4.5bn investment, creating 3600 jobs
AstraZeneca will develop a state-of-the-art manufacturing facility in Albemarle County, Virginia, producing a broader range of medicines, including weight management, metabolic and cancer therapies
Regulatory
Zelluna receives positive MHRA feedback and advances UK clinical plans for ZI-MA4-1
Zelluna has secured alignment with the UK’s MHRA on the clinical and regulatory pathway for its TCR-NK therapy ZI-MA4-1, paving the way for a CTA submission by the end of 2025 and first-in-human trials at The Christie and The Royal Marsden in 2026
Research & Development
Pharma leaders must separate AI hype from actionable opportunity, warns NIRAS
A new report from the company urges pharmaceutical executives to approach AI adoption with trust, transparency and traceability, outlining how the technology can drive compliance and productivity whilst warning against risks from poor data quality and opaque models